{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:25:20Z","timestamp":1791872720828,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Polymorphisms or mutations in hypoxia inducible factor-1 alpha (HIF-1alpha) that increases its activity and stability under normoxia have recently been identified. Likewise, disruption of the TSC1\/TSC2 complex through loss of TSC1 or TSC2 has been shown to result in abnormal accumulation of HIF-1\u03b1. Here, we investigate the novel polymorphisms in exon 12, that approximate the oxygen-dependent degradation domain of HIF-1alpha in five cell lines and 28 patients with oral squamous carcinomas. Moreover, we assess for the presence of polymorphisms and mutations in TSC1 and TSC2, to ascertain if dysregulation of such might complement HIF-1alpha expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Denaturing high pressure liquid chromatography (DHPLC) analysis on PCR fragments in exon 12 of HIF-1alpha from 28 patients with OSCC revealed that 6 of 28 patients had mismatched heteroduplex patterns. Genomic DNA was extracted from peripheral blood leukocytes and direct sequencing showed that in 5 of the six cases these changes represented polymorphisms while, one case was a somatic mutation. Analyses of TSC1 and TSC2 revealed heteroduplexes in exons: TSC1 exon 17; TSC2 exons 36,40, and 41. The relative levels of HIF-1alpha were significantly greater for tumors possessing a HIF-1alpha polymorphism or mutation within exon 12, whereas tumors possessing a deletion or polymorphism in TSC1\/TSC2 displayed a trend for higher levels of HIF-1alpha. Western blot analyses for HIF-1alpha, TSC1 and TSC2 in five SCC cell lines revealed high levels of HIF-1alpha in SCC cells possessing TSC1 and\/or TSC2 mutations. Wild-type TSC2 cells targeted with siRNA to TSC2 exhibited increased levels of HIF-1alpha. Transfection of a HIF-1alpha mutant produced higher levels of HIF-1alpha in TSC1\/TSC2 mutant cell lines than in wild type cells. TSC1\/TSC2 mutant cell lines administered Rapamycin blocked S6 phorphorylation and diminished the levels of HIF-1alpha to those observed in cell lines with wild type TSC1\/TSC2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Dysregulation of the TSC1\/TSC2 complex by mutation compliments HIF-1\u03b1 polymorphisms in the expression of HIF-1alpha in SCC of the head and neck, and may provide biomarkers to predict responses to specific therapies and overall disease prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-4598-5-3","type":"journal-article","created":{"date-parts":[[2006,1,23]],"date-time":"2006-01-23T12:43:57Z","timestamp":1138020237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Hypoxia-inducible factor-1\u03b1 polymorphisms and TSC1\/2 mutations are complementary in head and neck cancers"],"prefix":"10.1186","volume":"5","author":[{"given":"Carla","family":"Hebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Parashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Ord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G","family":"Nikitakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Sauk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,1,16]]},"reference":[{"key":"135_CR1","first-page":"5447","volume":"12","author":"GL Semenza","year":"1992","unstructured":"Semenza GL, Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992, 12: 5447-5454.","journal-title":"Mol Cell Biol"},{"key":"135_CR2","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995, 92: 5510-5514.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"135_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.1066373","volume":"294","author":"RK Bruick","year":"2001","unstructured":"Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001, 294: 1337-1340. 10.1126\/science.1066373","journal-title":"Science"},{"key":"135_CR4","doi-asserted-by":"publisher","first-page":"5197","DOI":"10.1093\/emboj\/20.18.5197","volume":"20","author":"N Masson","year":"2001","unstructured":"Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ: Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J. 2001, 20: 5197-5206. 10.1093\/emboj\/20.18.5197","journal-title":"Embo J"},{"key":"135_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0378-1119(01)00633-3","volume":"275","author":"MS Taylor","year":"2001","unstructured":"Taylor MS: Characterization and comparative analysis of the EGLN gene family. Gene. 2001, 275: 125-132. 10.1016\/S0378-1119(01)00633-3","journal-title":"Gene"},{"key":"135_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0960-894X(02)00219-6","volume":"12","author":"HKSGJMHLEONJMPHPCWRPJSCJ McNeill LA","year":"2002","unstructured":"McNeill LA HKSGJMHLEONJMPHPCWRPJSCJ: The use of dioxygen by HIF prolyl hydroxylase (PGD1). Bioorg Med Chem Lett. 2002, 12: 1547-1550. 10.1016\/S0960-894X(02)00219-6","journal-title":"Bioorg Med Chem Lett"},{"key":"135_CR7","doi-asserted-by":"publisher","first-page":"7987","DOI":"10.1073\/pnas.95.14.7987","volume":"95","author":"LE Huang","year":"1998","unstructured":"Huang LE, Gu J, Schau M, Bunn HF: Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998, 95: 7987-7992. 10.1073\/pnas.95.14.7987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"135_CR8","doi-asserted-by":"publisher","first-page":"22642","DOI":"10.1074\/jbc.272.36.22642","volume":"272","author":"S Salceda","year":"1997","unstructured":"Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997, 272: 22642-22647. 10.1074\/jbc.272.36.22642","journal-title":"J Biol Chem"},{"key":"135_CR9","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1074\/jbc.274.10.6519","volume":"274","author":"PJ Kallio","year":"1999","unstructured":"Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L: Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem. 1999, 274: 6519-6525. 10.1074\/jbc.274.10.6519","journal-title":"J Biol Chem"},{"key":"135_CR10","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1073\/pnas.080072497","volume":"97","author":"CH Sutter","year":"2000","unstructured":"Sutter CH, Laughner E, Semenza GL: Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A. 2000, 97: 4748-4753. 10.1073\/pnas.080072497","journal-title":"Proc Natl Acad Sci U S A"},{"key":"135_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.molcel.2005.01.011","volume":"17","author":"JH Baek","year":"2005","unstructured":"Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ, Semenza GL: OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell. 2005, 17: 503-512. 10.1016\/j.molcel.2005.01.011","journal-title":"Mol Cell"},{"key":"135_CR12","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1101\/gad.924501","volume":"15","author":"PC Mahon","year":"2001","unstructured":"Mahon PC, Hirota K, Semenza GL: FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15: 2675-2686. 10.1101\/gad.924501","journal-title":"Genes Dev"},{"key":"135_CR13","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1101\/gad.991402","volume":"16","author":"D Lando","year":"2002","unstructured":"Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002, 16: 1466-1471. 10.1101\/gad.991402","journal-title":"Genes Dev"},{"key":"135_CR14","doi-asserted-by":"publisher","first-page":"26351","DOI":"10.1074\/jbc.C200273200","volume":"277","author":"KS Hewitson","year":"2002","unstructured":"Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, Schofield CJ: Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002, 277: 26351-26355. 10.1074\/jbc.C200273200","journal-title":"J Biol Chem"},{"key":"135_CR15","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1073\/pnas.082121399","volume":"99","author":"SA Dames","year":"2002","unstructured":"Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE: Structural basis for Hif-1 alpha \/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci U S A. 2002, 99: 5271-5276. 10.1073\/pnas.082121399","journal-title":"Proc Natl Acad Sci U S A"},{"key":"135_CR16","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1074\/jbc.C200644200","volume":"278","author":"JM Elkins","year":"2003","unstructured":"Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, Pugh CW, Ratcliffe PJ, Schofield CJ: Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha. J Biol Chem. 2003, 278: 1802-1806. 10.1074\/jbc.C200644200","journal-title":"J Biol Chem"},{"key":"135_CR17","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1073\/pnas.082117899","volume":"99","author":"SJ Freedman","year":"2002","unstructured":"Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ: Structural basis for recruitment of CBP\/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A. 2002, 99: 5367-5372. 10.1073\/pnas.082117899","journal-title":"Proc Natl Acad Sci U S A"},{"key":"135_CR18","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/emboj\/cdg173","volume":"22","author":"Z Li","year":"2003","unstructured":"Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G: The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. Embo J. 2003, 22: 1857-1867. 10.1093\/emboj\/cdg173","journal-title":"Embo J"},{"key":"135_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/pros.20190","volume":"63","author":"XS Fu","year":"2005","unstructured":"Fu XS, Choi E, Bubley GJ, Balk SP: Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate. 2005, 63: 215-221. 10.1002\/pros.20190","journal-title":"Prostate"},{"key":"135_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.yexcr.2005.01.017","volume":"306","author":"M Hagg","year":"2005","unstructured":"Hagg M, Wennstrom S: Activation of hypoxia-induced transcription in normoxia. Exp Cell Res. 2005, 306: 180-191. 10.1016\/j.yexcr.2005.01.017","journal-title":"Exp Cell Res"},{"key":"135_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/00005537-200403000-00006","volume":"114","author":"NA Cohen","year":"2004","unstructured":"Cohen NA, Lai SY, Ziober AF, Ziober BL: Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential. Laryngoscope. 2004, 114: 418-423. 10.1097\/00005537-200403000-00006","journal-title":"Laryngoscope"},{"key":"135_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/93.4.309","volume":"93","author":"R Bos","year":"2001","unstructured":"Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001, 93: 309-314. 10.1093\/jnci\/93.4.309","journal-title":"J Natl Cancer Inst"},{"key":"135_CR23","first-page":"5830","volume":"59","author":"H Zhong","year":"1999","unstructured":"Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59: 5830-5835.","journal-title":"Cancer Res"},{"key":"135_CR24","first-page":"1830","volume":"61","author":"MI Koukourakis","year":"2001","unstructured":"Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL: Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001, 61: 1830-1832.","journal-title":"Cancer Res"},{"key":"135_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1006\/excr.2000.5139","volume":"264","author":"K Kondo","year":"2001","unstructured":"Kondo K, Kaelin WGJ: The von Hippel-Lindau tumor suppressor gene. Exp Cell Res. 2001, 264: 117-125. 10.1006\/excr.2000.5139","journal-title":"Exp Cell Res"},{"key":"135_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/carcin\/bgg132","volume":"24","author":"K Tanimoto","year":"2003","unstructured":"Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M: Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003, 24: 1779-1783. 10.1093\/carcin\/bgg132","journal-title":"Carcinogenesis"},{"key":"135_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.critrevonc.2004.09.009","volume":"56","author":"BK Law","year":"2005","unstructured":"Law BK: Rapamycin: An anti-cancer immunosuppressant?. Crit Rev Oncol Hematol. 2005, 56: 47-60.","journal-title":"Crit Rev Oncol Hematol"},{"key":"135_CR28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/humu.20227","volume":"26","author":"ND Rendtorff","year":"2005","unstructured":"Rendtorff ND, Bjerregaard B, Frodin M, Kjaergaard S, Hove H, Skovby F, Brondum-Nielsen K, Schwartz M: Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1\/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations. Hum Mutat. 2005, 26: 374-383. 10.1002\/humu.20227","journal-title":"Hum Mutat"},{"key":"135_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","volume":"8","author":"N Hay","year":"2005","unstructured":"Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005, 8: 179-183. 10.1016\/j.ccr.2005.08.008","journal-title":"Cancer Cell"},{"key":"135_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/0470869976.ch9","volume":"262","author":"T Nobukini","year":"2004","unstructured":"Nobukini T, Thomas G: The mTOR\/S6K signalling pathway: the role of the TSC1\/2 tumour suppressor complex and the proto-oncogene Rheb. Novartis Found Symp. 2004, 262: 148-54; discussion 154-9, 265-8.","journal-title":"Novartis Found Symp"},{"key":"135_CR31","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1083\/jcb.200405130","volume":"167","author":"E Goncharova","year":"2004","unstructured":"Goncharova E, Goncharov D, Noonan D, Krymskaya VP: TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol. 2004, 167: 1171-1182. 10.1083\/jcb.200405130","journal-title":"J Cell Biol"},{"key":"135_CR32","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/sj.onc.1205962","volume":"21","author":"A Astrinidis","year":"2002","unstructured":"Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP: Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene. 2002, 21: 8470-8476. 10.1038\/sj.onc.1205962","journal-title":"Oncogene"},{"key":"135_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/mc.10125","volume":"37","author":"S Li","year":"2003","unstructured":"Li S, Braverman R, Li H, Vass WC, Lowy DR, DeClue JE: Regulation of cell morphology and adhesion by the tuberous sclerosis complex (TSC1\/2) gene products in human kidney epithelial cells through increased E-cadherin\/beta-catenin activity. Mol Carcinog. 2003, 37: 98-109. 10.1002\/mc.10125","journal-title":"Mol Carcinog"},{"key":"135_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1081\/CNV-200027144","volume":"22","author":"BC Mak","year":"2004","unstructured":"Mak BC, Yeung RS: The tuberous sclerosis complex genes in tumor development. Cancer Invest. 2004, 22: 588-603. 10.1081\/CNV-200027144","journal-title":"Cancer Invest"},{"key":"135_CR35","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2174\/1566524043359610","volume":"4","author":"EP Henske","year":"2004","unstructured":"Henske EP: The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked?. Curr Mol Med. 2004, 4: 825-831. 10.2174\/1566524043359610","journal-title":"Curr Mol Med"},{"key":"135_CR36","first-page":"7652","volume":"63","author":"MA Knowles","year":"2003","unstructured":"Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D: Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res. 2003, 63: 7652-7656.","journal-title":"Cancer Res"},{"key":"135_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1034\/j.1600-0560.2002.290505.x","volume":"29","author":"R Wienecke","year":"2002","unstructured":"Wienecke R, Klemm E, Karparti S, Swanson NA, Green AJ, DeClue JE: Reduction of expression of tuberin, the tuberous-sclerosis-complex-gene-2 product in tuberous sclerosis complex associated connective tissue nevi and sporadic squamous and basal cell carcinomas. J Cutan Pathol. 2002, 29: 287-290. 10.1034\/j.1600-0560.2002.290505.x","journal-title":"J Cutan Pathol"},{"key":"135_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cancergencyto.2004.01.014","volume":"153","author":"M Ollerenshaw","year":"2004","unstructured":"Ollerenshaw M, Page T, Hammonds J, Demaine A: Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet. 2004, 153: 122-126. 10.1016\/j.cancergencyto.2004.01.014","journal-title":"Cancer Genet Cytogenet"},{"key":"135_CR39","first-page":"1033","volume":"12","author":"T Kuwai","year":"2004","unstructured":"Kuwai T, Kitadai Y, Tanaka S, Kuroda T, Ochiumi T, Matsumura S, Oue N, Yasui W, Kaneyasu M, Tanimoto K, Nishiyama M, Chayama K: Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. Oncol Rep. 2004, 12: 1033-1037.","journal-title":"Oncol Rep"},{"key":"135_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1476-4598-2-31","volume":"2","author":"MJ Percy","year":"2003","unstructured":"Percy MJ, Mooney SM, McMullin MF, Flores A, Lappin TR, Lee FS: A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. Mol Cancer. 2003, 2: 31- 10.1186\/1476-4598-2-31","journal-title":"Mol Cancer"},{"key":"135_CR41","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1158\/1078-0432.CCR-03-0249","volume":"10","author":"P Amornphimoltham","year":"2004","unstructured":"Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res. 2004, 10: 4029-4037. 10.1158\/1078-0432.CCR-03-0249","journal-title":"Clin Cancer Res"},{"key":"135_CR42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K","volume":"14","author":"Y Niida","year":"1999","unstructured":"Niida Y, Lawrence-Smith N, Banwell A, Hammer E, Lewis J, Beauchamp RL, Sims K, Ramesh V, Ozelius L: Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat. 1999, 14: 412-422. 10.1002\/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K","journal-title":"Hum Mutat"},{"key":"135_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","volume":"4","author":"JB Brugarolas","year":"2003","unstructured":"Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WGJ: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003, 4: 147-158. 10.1016\/S1535-6108(03)00187-9","journal-title":"Cancer Cell"},{"key":"135_CR44","unstructured":"Amornphimoltham PPVSANNGSJJSEAMAAGJS: mTOR, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck. Clin Cancer Res. ."},{"key":"135_CR45","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ejca.2005.03.023","volume":"41","author":"WG Jiang","year":"2005","unstructured":"Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, Mokbel K, Mansel RE: Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer. 2005, 41: 1628-1636. 10.1016\/j.ejca.2005.03.023","journal-title":"Eur J Cancer"},{"key":"135_CR46","doi-asserted-by":"publisher","first-page":"35664","DOI":"10.1074\/jbc.M403385200","volume":"279","author":"Z Lu","year":"2004","unstructured":"Lu Z, Hu X, Li Y, Zheng L, Zhou Y, Jiang H, Ning T, Basang Z, Zhang C, Ke Y: Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem. 2004, 279: 35664-35670. 10.1074\/jbc.M403385200","journal-title":"J Biol Chem"},{"key":"135_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s004390000316","volume":"106","author":"AC Jones","year":"2000","unstructured":"Jones AC, Sampson JR, Hoogendoorn B, Cohen D, Cheadle JP: Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis. Hum Genet. 2000, 106: 663-668. 10.1007\/s004390050040","journal-title":"Hum Genet"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-5-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:33:58Z","timestamp":1630452838000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-5-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,16]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-5-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,16]]},"assertion":[{"value":"3 October 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"3"}}